PDF(Pubmed)
Abstract：
The study aimed to investigate the BRAF V600E mutation and clinicopathological changes among patients with Hashimoto thyroiditis (HT), papillary thyroid carcinoma (PTC) with Hashimoto thyroiditis (HT), or nodular goiter (NG). A total of 87 patients with the BRAF V600E mutation who were diagnosed with HT (including with hyperplasia dysplasia), PTC with HT, and PTC with NG were enrolled. Clinical data, concentrations of antithyroglobulin antibodies (TGAb) and thyroid microsomal antibodies (TMAb) in the serum thyroid-function levels, and the result presence of the BRAF V600E mutation were retrospectively analyzed. There were significant differences in the BRAF V600E mutation rates between the HT and PTC with HT groups ( P <0.05) and the HT and PTC with NG groups ( P <0.05), whereas no significant difference was found between the PTC with HT and PTC with NG groups. There was no difference in incidences of PTC between HT with elevated TGAb and TMAb group and those with baseline levels. The incidence of multifocal PTC was higher in the PTC with HT group; however, the difference was not significant. Our findings documented that BRAF mutation distinguished between the benign HT and the malignant PTC groups. The serum levels of TGAb and TMAb autoantibodies did not directly correlate with PTC in the background of HT. HT and NG may similarly contribute to the pathogenesis of PTC.
摘要：
本研究旨在探讨桥本甲状腺炎(HT)患者BRAFV600E突变及临床病理改变,甲状腺乳头状癌（PTC）合并桥本甲状腺炎（HT），或结节性甲状腺肿（NG）。共有87例BRAFV600E突变患者被诊断为HT（包括增生性发育不良），带HT的PTC,并注册了带有NG的PTC。临床数据,血清甲状腺功能水平中抗甲状腺球蛋白抗体（TGAb）和甲状腺微粒体抗体（TMAb）的浓度，并对BRAFV600E突变的结果进行回顾性分析.HT和PTC伴HT组的BRAFV600E突变率(P<0.05)与HT和PTC伴NG组的BRAF突变率差异有统计学意义(P<0.05),而HT组的PTC和NG组的PTC之间没有显着差异。TGAb和TMAb升高的HT与基线水平的PTC发生率无差异。HT组的多焦点PTC发生率较高；然而，差异不显著。我们的发现证明BRAF突变可区分良性HT和恶性PTC组。在HT背景下，TGAb和TMAb自身抗体的血清水平与PTC没有直接相关。HT和NG可能同样有助于PTC的发病机理。
